ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Takeda promises more cost savings from Shire acquisition

Japanese drugmaker forecasts sales jump and lower profit in 'critical' 2019

Pharmaceutical maker Takeda says improvements in its supply chain, sales and marketing, and administrative efficiency will produce greater cost savings than it initially predicted.

TOKYO -- Takeda Pharmaceutical CEO Christophe Weber promised greater cost savings from the company's purchase of Irish drugmaker Shire, lifting the savings target by 43% versus its earlier forecast.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more